ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the Stocks That Could Mint Millionaires in 2026.
ADMA Biologics, Inc. (NASDAQ:ADMA) markets BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency, and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics.
In earnings for the third quarter of 2025, the firm provided updated guidance, noting that for 2025, total revenue was now expected to be $510 million, up from prior guidance of more than $500 million. The 2025 adjusted net income was also modestly adjusted to $158 million due to a higher effective tax rate.
ADMA Biologics, Inc. (NASDAQ:ADMA) is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
While we acknowledge the potential of ADMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for Long Term
Disclosure: None.
